HC Wainwright Increases Veru (NASDAQ:VERU) Price Target to $3.00

Veru (NASDAQ:VERU) had its price objective increased by analysts at HC Wainwright from $2.00 to $3.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 84.05% from the company’s current price.

A number of other brokerages also recently issued reports on VERU. Oppenheimer reissued an “outperform” rating and set a $5.00 price objective (down from $7.00) on shares of Veru in a research report on Monday, April 15th. Raymond James began coverage on shares of Veru in a research note on Thursday, March 28th. They issued an “outperform” rating and a $3.00 price target for the company.

Veru Stock Performance

Shares of Veru stock opened at $1.63 on Monday. Veru has a 52-week low of $0.36 and a 52-week high of $1.92. The company’s 50 day moving average price is $0.98 and its 200-day moving average price is $0.81. The stock has a market capitalization of $238.60 million, a price-to-earnings ratio of -2.17 and a beta of -0.47.

Veru (NASDAQ:VERU) last posted its earnings results on Monday, April 1st. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $2.14 million for the quarter. Veru had a negative return on equity of 257.92% and a negative net margin of 405.04%. As a group, equities research analysts forecast that Veru will post -0.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Veru

Institutional investors and hedge funds have recently made changes to their positions in the business. Choreo LLC bought a new position in Veru during the 1st quarter valued at approximately $64,000. Rosalind Advisors Inc. grew its stake in shares of Veru by 12.5% in the first quarter. Rosalind Advisors Inc. now owns 4,500,000 shares of the company’s stock worth $3,150,000 after acquiring an additional 500,000 shares during the last quarter. 180 Wealth Advisors LLC bought a new position in shares of Veru during the first quarter valued at $120,000. Perceptive Advisors LLC raised its position in shares of Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock worth $4,021,000 after purchasing an additional 4,494,821 shares during the last quarter. Finally, Octagon Capital Advisors LP bought a new position in Veru in the 4th quarter worth about $2,736,000. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.